CNSX:ABCS

Stock Analysis Report

Executive Summary

Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps.


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Abacus Health Products's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABCS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.2%

ABCS

-13.5%

CA Pharmaceuticals

-8.7%

CA Market


1 Year Return

-56.9%

ABCS

-65.5%

CA Pharmaceuticals

-4.6%

CA Market

Return vs Industry: ABCS exceeded the Canadian Pharmaceuticals industry which returned -65.6% over the past year.

Return vs Market: ABCS underperformed the Canadian Market which returned -2% over the past year.


Shareholder returns

ABCSIndustryMarket
7 Day4.2%-13.5%-8.7%
30 Day-8.5%-22.4%-7.5%
90 Day-34.2%-20.5%-5.5%
1 Year-56.9%-56.9%-65.5%-65.5%-1.7%-4.6%
3 Yearn/a-0.8%-1.5%7.4%-2.3%
5 Yearn/a277.7%277.7%24.6%6.3%

Price Volatility Vs. Market

How volatile is Abacus Health Products's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Abacus Health Products undervalued compared to its fair value and its price relative to the market?

2.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABCS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABCS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABCS is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: ABCS is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABCS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABCS is overvalued based on its PB Ratio (2x) compared to the CA Pharmaceuticals industry average (1.3x).


Next Steps

Future Growth

How is Abacus Health Products forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

54.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABCS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABCS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABCS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABCS's revenue (85.8% per year) is forecast to grow faster than the Canadian market (4.7% per year).

High Growth Revenue: ABCS's revenue (85.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABCS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Abacus Health Products performed over the past 5 years?

-1028.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ABCS is currently unprofitable.

Growing Profit Margin: ABCS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ABCS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ABCS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABCS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-11.3%).


Return on Equity

High ROE: ABCS has a negative Return on Equity (-37.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Abacus Health Products's financial position?


Financial Position Analysis

Short Term Liabilities: ABCS's short term assets ($36.7M) exceed its short term liabilities ($7.0M).

Long Term Liabilities: ABCS's short term assets ($36.7M) exceed its long term liabilities ($288.7K).


Debt to Equity History and Analysis

Debt Level: ABCS is debt free.

Reducing Debt: ABCS had no debt 5 years ago.


Balance Sheet

Inventory Level: ABCS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ABCS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABCS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ABCS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -94.6% each year


Next Steps

Dividend

What is Abacus Health Products's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.2%markettop25%6.0%industryaverage2.9%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ABCS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ABCS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABCS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABCS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABCS's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Perry Antelman (54yo)

1.1yrs

Tenure

US$153,217

Compensation

Mr. Perry Antelman serves as Chair of the Board at Abacus Health Products, Inc. He has been Chief Executive Officer of Abacus Health Products, Inc. since January 1, 2019 and also serves as its Director sin ...


CEO Compensation Analysis

Compensation vs Market: Perry's total compensation ($USD153.22K) is about average for companies of similar size in the Canadian market ($USD157.16K).

Compensation vs Earnings: Perry's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Perry Antelman
Chairman & CEO1.1yrsUS$153.22k8.41% $8.6m
Henry Hague
CFO & Secretary1.3yrsUS$214.89k0.00046% $470.7
Phillip Henderson
Senior VP of Corporate Development & Director1.1yrsUS$100.25k0.32% $323.3k
Charlie Hughes
Vice President of Operations (Aidance Scientific)0yrsno datano data
Bharat Madhavan
Chief Technology Officer0yrsno datano data
James Barkat
Vice President of Marketing0.8yrsno datano data
Mark Bolling
Vice President of Sales0.8yrsno datano data

1.0yrs

Average Tenure

50.5yo

Average Age

Experienced Management: ABCS's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Perry Antelman
Chairman & CEO1.1yrsUS$153.22k8.41% $8.6m
Phillip Henderson
Senior VP of Corporate Development & Director1.1yrsUS$100.25k0.32% $323.3k
Eyal Rosenthal
Independent Director1.3yrsUS$6.25kno data
Jesse Kaplan
Independent Director1.3yrsUS$6.25k0.12% $125.6k
Hannan Fleiman
Director0.6yrsno datano data

1.2yrs

Average Tenure

49.5yo

Average Age

Experienced Board: ABCS's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1846.5%.


Top Shareholders

Company Information

Abacus Health Products, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Abacus Health Products, Inc.
  • Ticker: ABCS
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$102.335m
  • Shares outstanding: 21.59m
  • Website: https://abacushp.com

Location

  • Abacus Health Products, Inc.
  • 10 Wanless Avenue
  • Suite 201
  • Toronto
  • Ontario
  • M4N 1V6
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABCSCNSX (Canadian National Stock Exchange)YesSubordinate Voting SharesCACADJan 2019
ABAH.FOTCPK (Pink Sheets LLC)YesSubordinate Voting SharesUSUSDJan 2019

Biography

Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The company offers CBD CLINIC line of products for relief from acute musculoskeletal and joint pain, which includes analgesic ointments, creams, and pain sticks, as well as analgesic massage oils. It also provides CBDMEDIC line of products, such as sport ointments and pain sticks, back and neck ointments, arthritis hand creams and ointments, and massage therapy oils, as well as ointments and pain sprays for muscles and joints. The company offers its CBD CLINIC products to registered health practitioners, including chiropractors, acupuncturists, massage and physical therapists, naturopaths, and osteopaths; and CBDMEDIC products directly to consumers through retail pharmacy chains and fitness locations, as well as online through the e-commerce platform. In addition, it is involved in developing a pipeline of other OTC CBD products addressing additional medical indications and the health and wellness sectors. The company is headquartered in Toronto, Canada. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/29 02:43
End of Day Share Price2020/02/28 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.